News & Updates

September 9, 2020

Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for PLG0206, the company's first-in-class, broad-spectrum antibiotic peptide, for the treatment of prosthetic joint infections (PJI), a rare life-threatening condition that may result from arthroplasty or joint replacement procedures.

"PLG0206 is the first novel anti-infective to be granted...

February 25, 2020

Peptilogics Receives CARB-X Award Worth up to $12.17M USD to Develop Lead Compound in Prosthetic Joint Infection and Accelerate Development of Additional Novel Antibiotics

Please reload

© 2020 Peptilogics  I  All Rights Reserved